SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

Date of Report (Date of earliest event reported): February 14, 2019
VARIAN MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-7598 94-2359345

(State or other jurisdiction

of incorporation)

(Commission File

Number)

(I.R.S. Employer

 Identification No.) 

 

3100 Hansen Way, Palo Alto, CA 94304-1030
(Address of principal executive offices, including zip code)
(650) 493-4000
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

The Annual Meeting of Stockholders of Varian Medical Systems, Inc. (the “Company”) was held on February 14, 2019 (the “Stockholders’ Meeting”). The Company’s stockholders voted on the following three proposals at the Stockholders’ Meeting and cast their votes as set forth in the following tables. Each of these proposals is described in detail in the Company’s Proxy Statement.

 

Proposal One:

 

Elect the following individuals as directors for one-year terms ending with the 2020 Annual Meeting of Stockholders:

 

  For Against Abstain Broker Non-Votes
Anat Ashkenazi 72,524,028 167,930 94,110 7,469,761
Jeffrey R. Balser 72,273,997 418,488 93,583 7,469,761
Judy Bruner 72,195,273 504,377 86,418 7,469,761
Jean-Luc Butel 72,330,693 364,726 90,649 7,469,761
Regina E. Dugan 71,982,526 717,338 86,204 7,469,761
R. Andrew Eckert 71,443,901 1,260,951 81,216 7,469,761
Timothy E. Guertin 72,188,825 516,305 80,938 7,469,761
David J. Illingworth 71,849,470 847,954 88,644 7,469,761
Dow R. Wilson 72,331,506 371,129 83,433 7,469,761

 

Proposal Two:

 

Approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers:

 

For Against Abstain Broker Non-Votes
68,056,711 4,563,376 165,981 7,469,761

 

Proposal Three:

 

Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2019:

 

For Against Abstain Broker Non-Votes (1)
77,376,298 2,750,766 128,765

 

(1) Pursuant to the rules of the New York Stock Exchange, this proposal constituted a routine matter. Therefore, brokers were permitted to vote without receipt of instructions from beneficial owners.

 

 

 

 

SIGNATURE(S)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Varian Medical Systems, Inc.
   
   
     
  By: /s/ John W. Kuo
  Name: John W. Kuo
  Title: Senior Vice President, General Counsel and Corporate Secretary

 

 

Dated: February 19, 2019